Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 583

1.

[BCG Immunotherapy Against Non-Muscle Invasive Bladder Cancer: Recent Results, Current Studies and Future Perspectives].

Takeuchi A, Shiota M, Tatsugami K, Yokomizo A, Eto M.

Fukuoka Igaku Zasshi. 2016 Jan;107(1):8-11. Japanese. No abstract available.

PMID:
27333654
2.

Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.

Takeuchi A, Eto M, Tatsugami K, Shiota M, Yamada H, Kamiryo Y, Dejima T, Kashiwagi E, Kiyoshima K, Inokuchi J, Takahashi R, Yokomizo A, Ohara N, Yoshikai Y.

Int Immunopharmacol. 2016 Jun;35:327-31. doi: 10.1016/j.intimp.2016.03.007. Epub 2016 Apr 16.

PMID:
27093372
3.

Prognosis of metastatic renal cell carcinoma with first-line Interferon-α therapy in the era of molecular-targeted therapy.

Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S.

Cancer Sci. 2016 Apr 18. doi: 10.1111/cas.12951. [Epub ahead of print]

4.

Equol inhibits prostate cancer growth via degradation of the androgen receptor by Skp2.

Itsumi M, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Naito S, Eto M, Yokomizo A.

Cancer Sci. 2016 Apr 18. doi: 10.1111/cas.12948. [Epub ahead of print]

5.

Domestic violence against women during pregnancy in Japan.

Suzuki S, Eto M.

J Matern Fetal Neonatal Med. 2016 Apr 28:1-2. [Epub ahead of print] No abstract available.

PMID:
27071842
6.

Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.

Shiota M, Eto M.

Int J Urol. 2016 May;23(5):360-9. doi: 10.1111/iju.13091. Epub 2016 Apr 8. Review.

PMID:
27062039
7.

CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma.

Motoshima T, Komohara Y, Horlad H, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M.

Oncol Lett. 2016 Mar;11(3):1911-1916. Epub 2016 Jan 20.

8.

Aldehyde dehydrogenase 2 (ALDH2) and alcohol dehydrogenase 1B (ADH1B) polymorphisms exacerbate bladder cancer risk associated with alcohol drinking: gene-environment interaction.

Masaoka H, Ito H, Soga N, Hosono S, Oze I, Watanabe M, Tanaka H, Yokomizo A, Hayashi N, Eto M, Matsuo K.

Carcinogenesis. 2016 Jun;37(6):583-8. doi: 10.1093/carcin/bgw033. Epub 2016 Mar 18.

PMID:
26992901
9.

Steroid co-introduction with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.

Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Shiga KI, Koga H, Yamaguchi A, Naito S, Eto M.

BJU Int. 2016 Mar 17. doi: 10.1111/bju.13483. [Epub ahead of print]

PMID:
26991851
10.

[Recent topics in the treatments of renal cell carcinoma].

Eto M.

Gan To Kagaku Ryoho. 2016 Jan;43(1):50-3. Japanese. No abstract available.

PMID:
26955665
11.

Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma.

Ma C, Komohara Y, Ohnishi K, Shimoji T, Kuwahara N, Sakumura Y, Matsuishi K, Fujiwara Y, Motoshima T, Takahashi W, Yamada S, Kitada S, Fujimoto N, Nakayama T, Eto M, Takeya M.

Cancer Sci. 2016 May;107(5):700-7. doi: 10.1111/cas.12917. Epub 2016 Apr 14.

12.

The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.

Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):191-6. doi: 10.1038/pcan.2016.2. Epub 2016 Feb 9.

PMID:
26857022
13.

Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association.

Koie T, Ohyama C, Fujimoto H, Nishiyama H, Miyazaki J, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T; Cancer Registration Committee of the Japanese Urological Association, Ohyama C, Nishiyama H, Fujisawa M, Uemura H, Fujimoto H, Suzuki K, Eto M, Hara I, Matsubara A, Nonomura N, Nakanishi H, Koie T, Kanayama H, Miki T, Fukumori T, Naito S; Cancer Registration Committee of the Japanese Urological Association.

Jpn J Clin Oncol. 2016 May;46(5):468-74. doi: 10.1093/jjco/hyw005. Epub 2016 Feb 6.

PMID:
26851754
14.

Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer.

Kiyoshima K, Akitake M, Shiota M, Takeuchi A, Takahashi R, Inokuchi J, Tatsugami K, Yokomizo A, Eto M.

Anticancer Res. 2016 Feb;36(2):799-802.

PMID:
26851042
15.

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy.

Shiota M, Yokomizo A, Eto M.

Front Oncol. 2016 Jan 11;5:304. doi: 10.3389/fonc.2015.00304. eCollection 2015. Review.

16.

Observation of a Biexciton Wigner Molecule by Fractional Optical Aharonov-Bohm Oscillations in a Single Quantum Ring.

Kim HD, Okuyama R, Kyhm K, Eto M, Taylor RA, Nicolet AL, Potemski M, Nogues G, Dang le S, Je KC, Kim J, Kyhm JH, Yoen KH, Lee EH, Kim JY, Han IK, Choi W, Song J.

Nano Lett. 2016 Jan 13;16(1):27-33. doi: 10.1021/acs.nanolett.5b02419. Epub 2015 Dec 14.

PMID:
26648477
17.

An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.

Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S, Ohyama C, Nasu Y, Tanaka M, Moriya F, Suekane S, Matsueda S, Komatsu N, Sasada T, Yamada A, Kakuma T, Itoh K.

Clin Cancer Res. 2016 Jan 1;22(1):54-60. doi: 10.1158/1078-0432.CCR-15-1265. Epub 2015 Nov 18.

PMID:
26581246
18.

Remodeling of the rat distal colon in diabetes: function and ultrastructure.

Siegman MJ, Eto M, Butler TM.

Am J Physiol Cell Physiol. 2016 Jan 15;310(2):C151-60. doi: 10.1152/ajpcell.00253.2015. Epub 2015 Nov 11.

PMID:
26561639
19.

Cancer du rein cliniquement localisé : quels sont les facteurs prédictifs du risque d'upstaging pathologique pT3a par invasion de la graisse ?

Bernhard J, Patard J, Bigot P, Suer E, Vuong N, Verhoest G, Alimi Q, Flamand V, Reix B, Beauval J, Benoit T, Nouhaud F, Lenormand C, Hamidi N, Eto M, Larre S, El Bakri A, Baco E, Ploussard G, Koutlidis N, Schneider A, Roupret M, Leon P, Carrouget J, Droupy S, Marchal S.

Prog Urol. 2015 Nov;25(13):800. doi: 10.1016/j.purol.2015.08.169. French. No abstract available.

PMID:
26544364
20.

Les résultats de la néphrectomie partielle pour les carcinomes chromophobes du rein sont excellents. Étude rétrospective multicentrique à partir de 234 cas.

Bigot P, Bernhard J, Gill I, Vuong N, Verhoest G, Flammand V, Reix B, Suer E, Gökce I, Beauval J, Nouhaud F, Eto M, Baco E, Matsugasumi T, Chowaniec Y, Rigaud J, Lenormand C, Pfister C, Hetet J, Ploussard G, Roupret M, Léon P, El Bakri A, Larré S, Tillou X, Doerfler A, Descazeaud A.

Prog Urol. 2015 Nov;25(13):800. doi: 10.1016/j.purol.2015.08.168. French. No abstract available.

PMID:
26544363
Items per page

Supplemental Content

Write to the Help Desk